Zealand Pharma kunne 30. september annoncere positive resultater fra fase 3-forsøg med glepaglutid hos patienter med korttarmssyndrom. Derudover har virksomheden netop sikret sig 786 mio. kr. fra salg af nye aktier. Dermed står Zealand Pharma stærkt i kommende forhandlinger med en potentiel partner og til udvikling af deres pipeline - som også indeholder spændende produkter inden for fedme. Hør mere i dette interview, hvor Helge Larsen et taget ud til Zealand Pharma for at tale med CEO Adam Steensberg.
Disclaimer: Zealand Pharma har betalt ir-samarbejde med ProInvestor.com.
Disclaimer: Zealand Pharma har betalt ir-samarbejde med ProInvestor.com.
Alt det vigtige omkring Zealand Pharma på små 10 minutter. Godt gået begge to. 
10/10 2022 15:16 collersteen 6
106851 Man kan i hvert fald sige, at kapitalrejsningen var flot og blev pænt modtaget. Den giver håb om, at investorerne ikke har afskrevet biotek fuldstændig.
Et supergodt interview og så endda med en lille breaking-nyhed til sidst omkring investorernes motivation mht. den seneste kapitalrejsning.
Iflg Jefferies kan salget af glepaglutid på sigt toppe i 580 mio. dollar om året. Det er ret vildt at tænke sig.
10/10 2022 17:19 ProInvestorNEWS 5106855 Zealand Pharma major shareholder announcement: Van Herk Investments
Company announcement - No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification dated 10 October 2022 pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As from 7 October 2022 Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,630,244 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 14,81% of the total share capital and total voting rights Zealand Pharma A/S.
Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.
Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,630,244 shares (each share carrying one vote), corresponding to 14,81% of the total share capital and total voting rights in Zealand Pharma A/S.
Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.
Please see further details in the attached notification forms.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com
Company announcement - No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification dated 10 October 2022 pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As from 7 October 2022 Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,630,244 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 14,81% of the total share capital and total voting rights Zealand Pharma A/S.
Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.
Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,630,244 shares (each share carrying one vote), corresponding to 14,81% of the total share capital and total voting rights in Zealand Pharma A/S.
Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.
Please see further details in the attached notification forms.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com
Zealand Pharma major shareholder announcement: Polar Capital
https://www.globenewswire.com/news-release/2022/10/11/2532149/0/en/Zealand-Pharma-major-shareholder-announcement-Polar-Capital.html
Zealand Pharma: Polar Capital ejer 11,51 pct. aktier.
https://www.globenewswire.com/news-release/2022/10/11/2532149/0/en/Zealand-Pharma-major-shareholder-announcement-Polar-Capital.html
Zealand Pharma: Polar Capital ejer 11,51 pct. aktier.
11/10 2022 17:36 ProInvestorNEWS 5106867 Company announcement - No. 47 / 2022
Zealand Pharma major shareholder announcement: Polar Capital
Copenhagen, Denmark and Boston, MA, 11 October 2022 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As of 10 October 2022, Polar Capital LLP holds nominally 5,930,317 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 11.51% of the total share capital and total voting rights in Zealand Pharma A/S.
Please see further details in the attached notification form.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com
Zealand Pharma major shareholder announcement: Polar Capital
Copenhagen, Denmark and Boston, MA, 11 October 2022 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As of 10 October 2022, Polar Capital LLP holds nominally 5,930,317 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 11.51% of the total share capital and total voting rights in Zealand Pharma A/S.
Please see further details in the attached notification form.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com
12/10 2022 07:18 ProInvestorNEWS 3106878 Zealand Pharma/Jefferies: Kursmål hæves til 205 kr. fra 165 kr. - NY
12/10 06:56
Zealand Pharma har fået løftet sit kursmål til 205 kr. fra 165 kr. hos Jefferies. Anbefalingen lyder fortsat "køb".
Det fremgår af et notat fra banken, efter at Zealand i de seneste par uger har præsenteret succesrige fase 3-data med lægemiddelkandidaten Glepaglutid til behandling af korttarmssyndrom og har rejst et stort trecifret millionbeløb.
- Positive fase 3-data med Glepaglutid i den sjældne sygdom korttarmssyndrom åbner mulighed for en kommerciel aftale, mens investorfokus sandsynligvis nu vil skifte til Zealands interessante tidlige portefølje af diabetes- og fedmemidler og peptidplatformen, skriver Jefferies' analyseteam.
Børshuset ser mulighed for yderligere samarbejder og partnerskaber inden for diabetes og fedme, og/eller at Zealand ender med at blive købt.
Aktien steg tirsdag 4,3 pct. til 169,80 kr.
.\˙ MarketWire
12/10 06:56
Zealand Pharma har fået løftet sit kursmål til 205 kr. fra 165 kr. hos Jefferies. Anbefalingen lyder fortsat "køb".
Det fremgår af et notat fra banken, efter at Zealand i de seneste par uger har præsenteret succesrige fase 3-data med lægemiddelkandidaten Glepaglutid til behandling af korttarmssyndrom og har rejst et stort trecifret millionbeløb.
- Positive fase 3-data med Glepaglutid i den sjældne sygdom korttarmssyndrom åbner mulighed for en kommerciel aftale, mens investorfokus sandsynligvis nu vil skifte til Zealands interessante tidlige portefølje af diabetes- og fedmemidler og peptidplatformen, skriver Jefferies' analyseteam.
Børshuset ser mulighed for yderligere samarbejder og partnerskaber inden for diabetes og fedme, og/eller at Zealand ender med at blive købt.
Aktien steg tirsdag 4,3 pct. til 169,80 kr.
.\˙ MarketWire
Fra Zealand Pharma-chatten i dag.
"Michael Novod's rapport i dag: Zealand Pharma - Buy/DKK 245: Amgen rallies 6%, adding USD ~7bn to its market cap on a ph I obesity asset - shows exactly how underappreciated the Zealand obesity pipeline is"
"Michael Novod's rapport i dag: Zealand Pharma - Buy/DKK 245: Amgen rallies 6%, adding USD ~7bn to its market cap on a ph I obesity asset - shows exactly how underappreciated the Zealand obesity pipeline is"
